Besides macrophages, T cells and TC‐1 cell lines can also be genetically engineered to construct stable PD‐1‐expressing cells and the corresponding GCMNs expressing PD‐1 for cancer immunotherapy.[16, 31]. This evidence concerns the gene PDCD1 and cancer.